Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Physiomics (LSE:PYC) Results Put Consultancy Demand, Cash Discipline and Growth Plans Under Review

Physiomics (LSE:PYC) is in focus following its final results and annual general meeting notice announcement on 13 October 2026. The development gives investors a fresh point at which to reassess the company’s strategy, execution priorities and the evidence needed to judge whether the announcement …

Ankur Sharma | 13 October 2026

IXICO Plc (LSE:IXI): AIM Market Spotlight as Investors Assess Pharmaceutical Clinical-Trial Services Demand

IXICO Plc (LSE:IXI) is an AIM-traded company whose investment case centres on imaging analytics for clinical trials. The current market discussion is shaped by pharmaceutical clinical-trial services demand. The central question for investors is whether strategic progress can translate into measurable operating outcomes rather …

Ankur Sharma | 13 October 2026

Abingdon Health (LSE:ABDX): Revenue Growth and H2 Profitability Mark a Key Test for Diagnostics Expansion

Abingdon Health is in focus following FY26 results showing strong revenue growth and adjusted EBITDA profitability in the second half, although the full year remained loss-making on an adjusted basis. Investors should distinguish a company-specific development from general attention around a small-cap share. Trading …

Ankur Sharma | 13 October 2026

Eden Biosolutions PLC (LSE:EDEN): AIM Market Spotlight as Investors Assess Commercial Execution

Eden Biosolutions PLC (LSE:EDEN) is an AIM-traded company whose investment case centres on biosolutions and life-science commercial opportunities. The current market discussion is shaped by commercial execution and product-market fit. The central question for investors is whether strategic progress can translate into measurable operating …

Ankur Sharma | 13 October 2026

How Surgical Innovations (LSE:SUN) is resetting under a new chief executive within the FTSE AIM All Share Index

Surgical Innovations designs and manufactures devices for minimally invasive surgery, including port access systems, instruments and retraction devices. Many of its products use a partly reusable "Resposable" concept, which aims to cut cost and waste. It also makes devices for OEM partners. Through its …

Divya Sood | 13 October 2026

How TheraCryf (LSE:TCF) plans to take its addiction drug into the clinic, and its place in the FTSE AIM All Share Index

Headquartered at Alderley Park in Cheshire, TheraCryf develops medicines for addiction and other neuropsychiatric disorders using a capital-light, virtual model. It aims to advance programmes to early clinical or proof-of-concept stage before seeking partners. Its lead asset is an orexin-1 receptor antagonist, known as …

Divya Sood | 13 October 2026

Why Futura Medical (LSE:FUM) Is Reshaping Its US Strategy as a FTSE AIM All Share Index Healthcare Stock

Futura Medical is a UK-based pharmaceutical company that develops sexual health products using its proprietary DermaSys transdermal delivery technology. Its lead product, Eroxon, is a topical gel for erectile dysfunction that is available without prescription in a number of markets. The company works through …

Ankur Sharma | 13 October 2026

Why GENinCode (LSE:GENI) investors are focused on the FDA within the FTSE AIM All Share Index

GENinCode develops genetic risk assessment tests that combine genetic information with clinical data to predict the risk of cardiovascular disease. Its main product, CARDIO inCode-Score, is designed to help clinicians identify patients at higher risk of coronary heart disease. The company sells in the …

Ankur Sharma | 13 October 2026

Scancell Holdings Plc (LSE:SCLP) in Focus: The Next Catalyst Investors Cannot Ignore

Scancell Holdings Plc (LSE:SCLP) is being assessed through the lens of its latest disclosed business position, sector conditions and upcoming execution milestones. Scancell is in focus after reporting preliminary results for the year ended 30 April 2026 and progressing financing and clinical-development milestones.

Ankur Sharma | 13 October 2026

Probiotix Health plc (LSE:PBX): What the AIM and London Market Is Watching Next

Probiotix Health plc (LSE:PBX) is drawing attention within the AIM market as investors weigh its latest company-specific developments against the wider outlook for probiotic strains and microbiome-related health ingredients. The central question on 13 October 2026 is whether the current investment narrative can translate …

Ankur Sharma | 13 October 2026
Support

Hi! How can we help you today?

Loading…